T <\/p>\n
he genomics pioneer who sequenced the human genome carved out a new niche just over a year ago,selling exhaustive $25,000 medicalworkupsto apparently healthy people.Now Craig Venters trying to take one small piece of that business to a much wider audience and to prove its worthwhile. <\/p>\n
An early step in that directioncame this month, when Venterscompany Human Longevitystruck a deal with a life insurer to boost its $2,500whole genome analysis product. For a discounted $1,400, customers and employees of the life insurer,MassMutual, can getevery inch of their DNA scoured and then interpreted for what it means for their disease risk. Its a way toturn risks into opportunities to outsmart the diseases that may lie in your future, Human Longevityswebsite says of the product. <\/p>\n
This is a STAT Plus article and is only available to STAT Plus subscribers. To read the full story, subscribe to STAT Plus or log in to your account. Good news: your first 30 days are on us. <\/p>\n
Rebecca Robbins can be reached at rebecca.robbins@statnews.com<\/a> Follow Rebecca on Twitter @rebeccadrobbins <\/p>\n <\/p>\n Link: T he genomics pioneer who sequenced the human genome carved out a new niche just over a year ago,selling exhaustive $25,000 medicalworkupsto apparently healthy people.Now Craig Venters trying to take one small piece of that business to a much wider audience and to prove its worthwhile. An early step in that directioncame this month, when Venterscompany Human Longevitystruck a deal with a life insurer to boost its $2,500whole genome analysis product. For a discounted $1,400, customers and employees of the life insurer,MassMutual, can getevery inch of their DNA scoured and then interpreted for what it means for their disease risk. Continue reading
\nCraig Venter wants $1,400 to sequence a genome. Is it worth it? - Stat - STAT<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"